tiprankstipranks
Daewon Pharmaceutical Co., Ltd (KR:003220)
:003220
South Korea Market
003220
Daewon Pharmaceutical Co., Ltd
RESEARCH TOOLSreports

Daewon Pharmaceutical Co., Ltd (003220) Financial Statements

― Followers

Daewon Pharmaceutical Co., Ltd Financial Overview

Daewon Pharmaceutical Co., Ltd's market cap is currently ₩173.77B. The company's EPS TTM is $122.58; its P/E ratio is 65.02; and it has a dividend yield of 3.14%. Daewon Pharmaceutical Co., Ltd is scheduled to report earnings on August 7, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue₩ 605.64B₩ 598.16B₩ 526.95B₩ 478.88B₩ 354.18B
Gross Profit₩ 266.09B₩ 287.33B₩ 254.23B₩ 237.94B₩ 176.47B
Operating Income₩ 3.48B₩ 28.22B₩ 32.23B₩ 43.01B₩ 19.43B
EBITDA₩ 27.23B₩ 45.56B₩ 48.01B₩ 61.77B₩ 37.11B
Net Income₩ -1.38B₩ 14.21B₩ 23.92B₩ 31.94B₩ 6.99B
Balance Sheet
Cash & Short-Term Investments₩ 76.48B₩ 46.11B₩ 30.03B₩ 47.01B₩ 54.82B
Total Assets₩ 613.65B₩ 583.39B₩ 508.00B₩ 453.55B₩ 429.58B
Total Debt₩ 187.08B₩ 187.24B₩ 146.05B₩ 116.48B₩ 123.97B
Net Debt₩ 139.89B₩ 170.18B₩ 116.07B₩ 89.51B₩ 82.27B
Total Liabilities₩ 335.21B₩ 298.81B₩ 243.73B₩ 204.78B₩ 211.18B
Stockholders' Equity₩ 265.92B₩ 275.28B₩ 266.20B₩ 250.95B₩ 219.30B
Cash Flow
Free Cash Flow₩ 13.78B₩ -23.55B₩ 31.12B₩ 19.96B₩ 10.71B
Operating Cash Flow₩ 43.58B₩ 30.04B₩ 51.73B₩ 33.33B₩ 22.41B
Investing Cash Flow₩ -12.99B₩ -42.98B₩ -68.27B₩ -27.69B₩ -41.62B
Financing Cash Flow₩ 6.60B₩ -297.81M₩ 19.51B₩ -20.41B₩ 48.53B
Currency in KRW

Daewon Pharmaceutical Co., Ltd Earnings and Revenue History

Income Statement >

Daewon Pharmaceutical Co., Ltd Debt to Assets

Balance Sheet >

Daewon Pharmaceutical Co., Ltd Cash Flow

Cash Flow >

Daewon Pharmaceutical Co., Ltd Forecast EPS vs Actual EPS

Earnings >